NASDAQ · EYPT
Healthcare · Biotechnology
$2.99
Down-$0.15 (-4.78%)
Updated Oct 19, 2026, 9:38 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · EYPT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 16, 2026
EYPT closed at $2.99 after 20 trading sessions, down 25.62% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | $3.14 | $3.15 | $2.9512 | $2.99 | 2.76M |
| Oct 15, 2026 | $3.02 | $3.175 | $3.009 | $3.14 | 2.84M |
| Oct 14, 2026 | $3.04 | $3.055 | $2.93 | $3.01 | 3.16M |
| Oct 13, 2026 | $3.30 | $3.315 | $3.06 | $3.07 | 2.52M |
| Oct 12, 2026 | $3.42 | $3.4299 | $3.285 | $3.32 | 1.9M |
| Oct 9, 2026 | $3.44 | $3.5685 | $3.38 | $3.40 | 1.94M |
| Oct 8, 2026 | $3.30 | $3.52 | $3.27 | $3.46 | 3.26M |
| Oct 7, 2026 | $3.15 | $3.42 | $3.08 | $3.32 | 3.02M |
| Oct 6, 2026 | $3.18 | $3.29 | $3.075 | $3.17 | 1.98M |
| Oct 5, 2026 | $3.28 | $3.28 | $3.05 | $3.15 | 2.76M |
| Oct 2, 2026 | $3.31 | $3.31 | $3.10 | $3.25 | 3.11M |
| Oct 1, 2026 | $3.29 | $3.45 | $3.23 | $3.23 | 2.86M |
| Sep 30, 2026 | $3.42 | $3.46 | $3.25 | $3.27 | 3.44M |
| Sep 29, 2026 | $3.31 | $3.50 | $3.2994 | $3.42 | 2.54M |
| Sep 28, 2026 | $3.58 | $3.60 | $3.265 | $3.31 | 3.3M |
| Sep 25, 2026 | $3.65 | $3.705 | $3.555 | $3.62 | 2.25M |
| Sep 24, 2026 | $3.71 | $3.725 | $3.54 | $3.65 | 2.3M |
| Sep 23, 2026 | $4.10 | $4.1818 | $3.705 | $3.72 | 2.02M |
| Sep 22, 2026 | $4.08 | $4.215 | $3.9723 | $4.07 | 4.46M |
| Sep 21, 2026 | $3.87 | $4.10 | $3.80 | $4.02 | 3.86M |
The latest Smart Investors Daily articles mentioning EYPT.
Company
Market Activity
Research & News
EYPT research
Company profile and research snapshot.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | TD Cowen | Hold | — |
| Aug 18, 2026 | RBC Capital | Sector Perform | — |
| Aug 18, 2026 | Chardan Capital | Neutral | — |
| Aug 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 18, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 18, 2026
U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
Yahoo · Sep 16, 2026
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,00
SeekingAlpha · Sep 15, 2026
EyePoint, Inc. (EYPT) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 7:00 AM EDTCompany ParticipantsJay Duker - President, CEO...
SeekingAlpha · Sep 9, 2026
EyePoint, Inc. (EYPT) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 8:00 AM EDTCompany ParticipantsJay Duker - President, CEO &...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EYPT.
